Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye – evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN®),Journal of Ophthalmic Inflammation and Infection

当前位置： X-MOL 学术 › J. Ophthal. Inflamm. Infect. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye – evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN®)
Journal of Ophthalmic Inflammation and Infection ( IF 2.9 ) Pub Date : 2020-11-30 , DOI: 10.1186/s12348-020-00225-z
Bahram Bodaghi ₁ , Quan Dong Nguyen ₂ , Glenn Jaffe ₃ , Ramin Khoramnia ₄ , Carlos Pavesio ₅

Affiliation

The current article is a short review of an Alimera Sciences-sponsored symposium held during The 15th International Ocular Inflammation Society Congress in Taiwan on the 14th November 2019 entitled, ‘Preventing relapse of non-infectious uveitis effecting the posterior segment of the eye – evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant.’ The fluocinolone acetonide intravitreal implant was approved in Europe for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye and offers a systemic therapy-sparing treatment option by providing low daily dose of corticosteroid into the vitreous for up to 3 years. In the symposium, the presenters reported clinical outcomes from patients with non-infectious uveitis effecting the posterior segment of the eye to support the effectiveness and safety of the implant for up to 3 years in both randomised controlled trials and real-world practices. Data showed that over a 36 month period, treatment with the fluocinolone acetonide intravitreal implant was associated with significantly fewer episodes of uveitic recurrence, a significantly longer time to uveitic recurrence, greater improvement in visual acuity, a lower need for adjunctive therapy, and an acceptable safety profile.

更新日期：2020-12-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文